

## Supplemental Material and Methods

### Virus production and transduction

Lentiviral particles (for stable integration of shRNA or CRISPR/Cas9 constructs) were produced in HEK293T cells with 3<sup>rd</sup> generation packaging plasmids (Addgene 12259 and 12259) and the respective transfer plasmid using calcium phosphate. Virus containing supernatant was concentrated using Amicon Ultra centrifugal filter units (Merck Millipore) and cells transduced with hexadimethrine bromide (Sigma-Aldrich). Transduced cells were selected with puromycin or sorted by flow cytometry based on expression of blue fluorescent protein (BFP).

### Site-directed mutagenesis

Site-directed mutagenesis was performed using the GeneArt Site-Directed Mutagenesis System (Thermo Fisher Scientific) according to manufacturer's protocol.

### Immunoblotting

Cells were lysed with RIPA buffer (see below), suspended in 4xLDS loading buffer (Thermo Fisher Scientific) supplemented with 250 mmol/L 1,4-Dithiothreitol (DTT, Sigma-Aldrich). After boiling the samples at 70°C for 5 minutes, proteins were separated by electrophoresis on 4-12% gradient polyacrylamide gels (Life Technologies). Proteins were transferred onto a Protran™ nitrocellulose membrane (GE Healthcare). Membranes were blocked in 5% (w/v) milk powder in Tris-buffered saline (TBS)/0.01% Tween20 (Sigma-Aldrich) and incubated overnight with primary antibodies at 4°C. Membranes were washed in TBS/Tween and incubated with horseradish peroxidase (HRP)-coupled IgG secondary antibody for 1h at room temperature. Membranes were washed in TBS/Tween and proteins were detected using ECL detection reagent (Thermo Fisher Scientific) in a ChemiDoc™ Touch Imaging system (BioRad).

### RIPA buffer

Before use, buffer was supplemented with protease inhibitor (Roche Complete Mini)

Tris-Cl pH=7.5	50 mmol/L
Sodium chloride	150 mmol/L
NP-40	1%
Sodium deoxycholate	0.5%

Sodium dodecyl sulfate	0.1%
EGTA	1 mmol/L
Sodium fluoride	50 mmol/L
Beta glycerolphosphate	10 mmol/L
Sodium pyrophosphate	5 mmol/L
Sodium ortho vanadate	1 mmol/L

### Co-Immunoprecipitation

Cells were lysed in ice cold Co-IP buffer (see below) and disrupted using syringes. Lysates were incubated with Protein G Dynabeads (Thermo Fisher Scientific)/antibody conjugates or beads alone for 3h at 4°C. Beads were washed and bound protein was released by boiling the beads in LDS buffer (as described above) at 70°C for 5 minutes.

#### CoIP buffer

Before use, buffer was supplemented with protease inhibitor (Roche Complete Mini)

Tris-Cl pH=7.5	50 mmol/L
Sodium chloride	80 mmol/L
NP-40	0.3%
Glycerol	10%
Magnesium chloride	1.5 mmol/L
Sodium fluoride	25 mmol/L
Beta glycerolphosphate	10 mmol/L
Sodium pyrophosphate	5 mmol/L
Sodium ortho vanadate	2 mmol/L

### Generation of shRNA cell lines

Custom designed shRNAs in Lentiviral vectors (Cellecta) to transduce target cells with either the targeting shRNA plasmid (shP3F) or the non-targeting control shRNA plasmid (shscr) were ordered (Suppl.Fig.1A) (Cellecta):

HEK293T cells were co-transfected with the transfer plasmid, the envelope plasmid, and packaging plasmids. 48h after transfection viral supernatant was collected and concentrated using Amicon® Ultra Centrifugal Filters (Merck Millipore) according to manufacturer's protocol. Cell lines were transduced with viral concentrate in medium containing 8 µg/mL Hexadimethrine bromide (Sigma). Cells from PDXs were transduced without Hexadimethrine bromide. After 72h cells were selected with 0.5 µg/mL

Puromycin (Sigma). In advance we tested three different shP3F sequences targeting the breakpoint region for knockdown efficiency and toxicity and continued with shP3F #3.

Targeting sequences

#1 CCTCTCACCTCAGAATTCAAT  
#2 CTCTCACCTCAGAATTCAATT  
**#3 GGCCTCTCACCTCAGAATTCA**

### qRT-PCR

RNA was isolated from cells using the RNeasy Mini Kit (Qiagen). 1 µg of RNA was transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Real-time PCR was performed using TaqMan probes (see below) and the TaqMan Gene Expression Master Mix (both Thermo Fisher Scientific). Expression changes were calculated using the  $\Delta\Delta C_t$  method with GAPDH as internal control.

TaqMan probes

All probes were ordered as Assay-on-Demand mix (Thermo Fisher Scientific) containing specific primers and FAM/BHQ-1 probe.

Gene	Assay ID
PAX3-FOXO1	Hs03024825
GAPDH	Hs02758991_g1
PMAIP1 (NOXA)	Hs00560402
MYCN	Hs00232074
MDM2	Hs01066930

### Immunohistochemistry (IHC) of tissue microarray (TMA) and analysis of gene expression profiling data

4 micron sections of a previously described TMA [49] representing samples from 81 RMS cases were stained using primary antibodies for Aurora Kinase (1:50 dilution, rabbit anti-AK2-L, JLM28, Leica, UK) or Ki67 (1:100 dilution, mouse anti-MIB-1, M7240, Dako, UK) with the Roche Ventana Benchmark Ultra © automated system. Positive controls included bowel, testis and tissue culture preparations whilst the protocol without the primary antibody was used as a negative control.

Stained TMAs were scored by two histopathologists (AK, GP) with discrepant scoring discussed in real time. Aurora Kinase staining in tumour cells was assessed for intensity of staining (1-weak, 2-intermediate or 3-strong) and the percentage of positive cells (1 (<30%), 2 (30-60%) and 3 (>60%) of cells). Ki67 staining was assessed for percentage of tumor cells positive. A combined metric was created

for AURKA by multiplying the intensity score by the percentage positivity score and averaged over all scorable cores per sample. An overall score of negative (0), weak (<3 combined score), moderate (3-6 combined score) and strong (>6 combined score) was then applied. Our previously described ITCC gene expression profiling data [4] was analyzed using the open access platform R2 Genomics and Visualization Platform (<http://r2.amc.nl>).

## Antibodies

Antigen	Manufacturer	Host (Clone)	Dilution
AURORA A	Genetex	ms mono (35C1)	1:1000
BAD	Cell signaling	rb mono (D24A9)	1:1000
BAK	Cell signaling	rb poly	1:1000
BAX	Cell signaling	rb poly	1:1000
BIM	Santa Cruz	ms mono (H-5)	1:500
CASP9	Cell signaling	ms mono (C9)	1:1000
Cl. CASP3	Cell signaling	rb mono (D175)	1:1000
Cl. CASP7	Cell signaling	rb poly (D198)	1:1000
FOXO1	Santa Cruz	rb poly (H-128)	1:500
GAPDH	Cell signaling	rb mono (14C10)	1:1000
MYCN	Cell signaling	rb mono	1:1000
NOXA	Cell signaling	rb mono (D8L7U)	1:1000
P21	Cell signaling	rb mono (12D1)	1:1000
P53	Thermo Fisher Sc	ms mono (DO-1)	1:1000
PARP	Cell signaling	rb poly	1:1000
PLK1	Merck Millipore	ms mono	1:1000
pFOXO1 <sub>(S256 ⇌ S437)</sub>	Cell signaling	rb poly	1:750
pPLK1 <sub>(T210)</sub>	Cell signaling	rb mono (D5H7)	1:750
XIAP	Cell signaling	rb poly	1:1000

*ms: mouse / rb: rabbit*

**Supplemental Table 1: Drug library content**

Product Name	Target
Veliparib (ABT-888)	PARP
Axitinib	VEGFR, PDGFR, c-Kit
Saracatinib (AZD0530)	Src, Bcr-Abl
FG-4592	HIF
Afatinib (BIBW2992)	EGFR
Bortezomib (PS-341)	Proteasome
Bosutinib (SKI-606)	Src
Dovitinib (TKI-258, CHIR-258)	c-Kit, FGFR, Flt, VEGFR, PDGFR
Dasatinib	Src, Bcr-Abl, c-Kit
Erlotinib HCl (OSI-744)	EGFR

<b>Gefitinib (ZD1839)</b>	EGFR
<b>Lapatinib (GW-572016)</b>	EGFR, HER2
<b>Lenalidomide (CC-5013)</b>	TNF-alpha
<b>Nilotinib (AMN-107)</b>	Bcr-Abl
<b>Pazopanib HCl</b>	VEGFR, PDGFR, c-Kit
<b>Rapamycin (Sirolimus)</b>	mTOR
<b>Sorafenib Tosylate</b>	VEGFR, PDGFR, Raf
<b>Sunitinib Malate</b>	VEGFR, PDGFR, c-Kit, Flt
<b>Vandetanib (ZD6474)</b>	VEGFR
<b>Vorinostat (SAHA, MK0683)</b>	HDAC
<b>VX-680 (Tozasertib, MK-0457)</b>	Aurora Kinase
<b>Y-27632 2HCl</b>	ROCK
<b>Elesclomol (STA-4783)</b>	HSP
<b>Entinostat (MS-275)</b>	HDAC
<b>Enzastaurin (LY317615)</b>	PKC
<b>Olaparib (AZD2281, Ku-0059436)</b>	PARP
<b>GDC-0941</b>	PI3K
<b>SB431542</b>	TGF-beta/Smad
<b>Crizotinib (PF-02341066)</b>	c-Met, ALK
<b>AUY922 (NVP-AUY922)</b>	HSP
<b>PHA-665752</b>	c-Met
<b>SB216763</b>	GSK-3
<b>MK-2206 2HCl</b>	Akt
<b>Vismodegib (GDC-0449)</b>	Hedgehog, P-gp
<b>KU-55933 (ATM Kinase Inhibitor)</b>	ATM
<b>GSK1904529A</b>	IGF-1R
<b>MLN8054</b>	Aurora Kinase
<b>Danusertib (PHA-739358)</b>	Aurora Kinase, FGFR, Bcr-Abl, c-RET, Src
<b>GSK690693</b>	Akt
<b>JNJ-38877605</b>	c-Met
<b>Palbociclib (PD-0332991) HCl</b>	CDK
<b>Cabozantinib (BMS-907351)</b>	VEGFR, c-Met, Flt, Tie-2, c-Kit
<b>Everolimus (RAD001)</b>	mTOR
<b>BMS-754807</b>	IGF-1R
<b>YM155 (Sapantronium Bromide)</b>	Survivin
<b>Alisertib (MLN8237)</b>	Aurora Kinase
<b>AT9283</b>	Bcr-Abl, JAK, Aurora Kinase
<b>Barasertib (AZD1152-HQPA)</b>	Aurora Kinase
<b>Roscovitine (Seliciclib,CYC202)</b>	CDK
<b>Lenvatinib (E7080)</b>	VEGFR
<b>Valproic acid</b>	GABA Receptor, HDAC
<b>CYC116</b>	Aurora Kinase, VEGFR
<b>XAV-939</b>	Wnt/beta-catenin
<b>Thalidomide</b>	Others
<b>Decitabine</b>	DNA/RNA Synthesis
<b>PIK-75</b>	PI3K, DNA-PK

<b>2-Methoxyestradiol (2-MeOE2)</b>	HIF
<b>Vemurafenib (PLX4032, RG7204)</b>	Raf
<b>Rigosertib (ON-01910)</b>	PLK
<b>Ruxolitinib (INCB018424)</b>	JAK
<b>Resveratrol</b>	Sirtuin
<b>Ispinesib (SB-715992)</b>	Kinesin
<b>AEE788 (NVP-AEE788)</b>	EGFR, Flt, VEGFR, HER2
<b>PHA-793887</b>	CDK
<b>Ponatinib (AP24534)</b>	Bcr-Abl, VEGFR, FGFR, PDGFR, Flt
<b>AT7519</b>	CDK
<b>MK-1775</b>	Wee1
<b>Quizartinib (AC220)</b>	Flt
<b>AZD7762</b>	Chk
<b>R406 (free base)</b>	Syk
<b>Org 27569</b>	Cannabinoid Receptor
<b>EX 527 (Selisistat)</b>	Sirtuin
<b>Pomalidomide</b>	TNF-alpha, COX
<b>KU-60019</b>	ATM
<b>BIRB 796 (Doramapimod)</b>	p38 MAPK
<b>RO4929097</b>	Y-Secretase
<b>Tie2 kinase inhibitor</b>	Tie-2
<b>Azacitidine</b>	DNA/RNA Synthesis
<b>Acadesine</b>	AMPK
<b>Nicorandil</b>	Others
<b>PF-573228</b>	FAK
<b>Lovastatin</b>	HMG-CoA Reductase
<b>LDE225 (Erismodegib)</b>	Smoothed
<b>PF-4708671</b>	S6 Kinase
<b>MLN2238</b>	Proteasome
<b>MLN9708</b>	Proteasome
<b>SGI-1776 free base</b>	Pim
<b>AZ 960</b>	JAK
<b>Apatinib</b>	VEGFR
<b>Volasertib (BI 6727)</b>	PLK
<b>Degrasyn (WP1130)</b>	DUB, Bcr-Abl
<b>BKM120 (Buparlisib)</b>	PI3K
<b>Imatinib (STI571)</b>	PDGFR,c-Kit, v-Abl
<b>Mifepristone</b>	Estrogen/progestogen Receptor
<b>LY2603618</b>	Chk
<b>NU7441 (KU-57788)</b>	DNA-PK, PI3K
<b>MK-0752</b>	Gamma-secretase
<b>Trametinib (GSK1120212)</b>	MEK
<b>Ibrutinib (PCI-32765)</b>	Src
<b>NVP-BSK805 2HCl</b>	JAK
<b>GDC-0980 (RG7422)</b>	mTOR, PI3K
<b>A-769662</b>	AMPK

<b>AMG-900</b>	Aurora Kinase
<b>Crenolanib (CP-868596)</b>	PDGFR
<b>AZ 3146</b>	Kinesin
<b>PHA-767491</b>	CDK
<b>CUDC-907</b>	HDAC, PI3K
<b>NVP-BVU972</b>	c-Met
<b>SB705498</b>	TRPV
<b>Tofacitinib (CP-690550)</b>	JAK
<b>Dabrafenib (GSK2118436)</b>	Raf
<b>GDC-0068</b>	Akt
<b>Torin 2</b>	mTOR
<b>TAE226 (NVP-TAE226)</b>	FAK
<b>TPCA-1</b>	IKK
<b>Carfilzomib (PR-171)</b>	Proteasome
<b>T0070907</b>	PPAR
<b>WZ811</b>	CXCR
<b>IOX2</b>	HIF
<b>Evacetrapib (LY2484595)</b>	CETP
<b>Pazopanib</b>	VEGFR
<b>Rimonabant</b>	Cannabinoid Receptor
<b>Cabozantinib malate</b>	c-met, VEGFR2
<b>Spironolactone</b>	Androgen Receptor
<b>JNK-IN-8</b>	Free Base
<b>QNZ (EVP4593)</b>	NF-κB
<b>Tofacitinib (CP-690550) Citrate</b>	JAK
<b>GDC-0152</b>	IAP
<b>AZD3514</b>	Androgen Receptor
<b>AZ20</b>	ATM/ATR
<b>GSK126</b>	Histone Methyltransferase
<b>EPZ5676</b>	Methyltransferase
<b>GSK J4 HCl</b>	Others
<b>LDK378</b>	ALK
<b>IWP-2</b>	Wnt/beta-catenin
<b>GSK2334470</b>	PDK-1
<b>PF-3758309</b>	PAK
<b>HSP990 (NVP-HSP990)</b>	HSP (e.g. HSP90)
<b>AZD3463</b>	ALK
<b>EPZ-6438</b>	Histone Methyltransferase
<b>PYR-41</b>	E1 Activating
<b>PR-619</b>	DUB
<b>P5091 (P005091)</b>	DUB
<b>BMS-833923</b>	Hedgehog/Smoothed
<b>AZD1080</b>	GSK-3
<b>C646</b>	Histone Acetyltransferase
<b>10058-F4</b>	c-Myc
<b>AVL-292</b>	BTK

<b>IOX1</b>	Histone demethylases
<b>OG-L002</b>	Histone demethylases
<b>SGC-CBP30</b>	Epigenetic Reader Domain
<b>CNX-774</b>	BTK
<b>MM-102</b>	Histone Methyltransferase
<b>JIB-04</b>	Histone demethylases
<b>PFI-2</b>	Histone Methyltransferase
<b>CPI-203</b>	Epigenetic Reader Domain
<b>GSK2606414</b>	PERK
<b>6H05</b>	Rho
<b>K-Ras(G12C) inhibitor 9</b>	Rho
<b>SH-4-54</b>	STAT
<b>OTX015</b>	BET
<b>LEE011</b>	CDK
<b>LDC000067</b>	CDK
<b>PI-1840</b>	Proteasome
<b>JNK Inhibitor IX</b>	JNK
<b>GNF-5837</b>	Trk receptor
<b>Afuresertib (GSK2110183)</b>	Akt
<b>GDC-0994</b>	ERK
<b>UNC0379</b>	Histone Methyltransferase
<b>GSK-LSD1 2HCl</b>	Histone Demethylase
<b>GSK J1</b>	Histone Demethylase
<b>INCB024360</b>	IDO
<b>BRD4770</b>	Histone Methyltransferase
<b>BV-6</b>	IAP
<b>EI1</b>	Histone Methyltransferase
<b>MI-2 (Menin-MLL Inhibitor)</b>	Histone Methyltransferase
<b>LDC1267</b>	Axl
<b>CPI-360</b>	Histone Methyltransferase
<b>CH5183284 (Debio-1347)</b>	FGFR
<b>YK-4-279</b>	DNA/RNA Synthesis
<b>AZD6738</b>	ATM/ATR
<b>Verdinexor (KPT-335)</b>	CRM1
<b>EPZ015666</b>	Histone Methyltransferase
<b>Pexmetinib (ARRY-614)</b>	p38 MAPK
<b>Pexidartinib (PLX3397)</b>	CSF-1R
<b>BI-847325</b>	MEK
<b>PFI-4</b>	Epigenetic Reader Domain
<b>Epacadostat (INCB024360)</b>	IDO
<b>NSC 23766</b>	Rac
<b>BMS-345541</b>	IκB/IKK
<b>Pacritinib (SB1518)</b>	JAK
<b>Idasanutlin</b>	MDM2/p53
<b>iBet762</b>	BET
<b>ABT-263</b>	BCL2, BCL-XL, BCL-w
<b>ABT-199</b>	BCL2
<b>Obatoclax</b>	BCL2-family



<b>Dynasore</b>	Dynamin
<b>Dyngo4a</b>	Dynamin
<b>GDC-0973</b>	MEK
<b>Fenretinide</b>	Retinoid Acid Receptor
<b>JQ-1</b>	BET
<b>Birinapant</b>	IAP
<b>Doxorubicine</b>	DNA
<b>Vincristine</b>	Microtubuli
<b>Etoposide</b>	Topoisomerase